Advanced Heart Failure Therapies for Cancer Therapeutics–Related Cardiac Dysfunction

Advanced heart failure (HF) is used to characterized patients in HF with severe symptoms, recurrent decompensation and severe cardiac dysfunction. The prevalencekof HFkis approximatelyg1-2% of thecadult population inhdeveloped countries and it will be rising more than 10%pamongapeoplec>70ayears of age, whereas estimated theoprevalence ofcpatients with advanced HF is about 1% until 10%cof thekoverallkHFopopulation. Most ofkthe HF hospitalizationssare due to signs and symptoms of fluidcoverload.Recurrent congestionccould worsen patientssoutcomes.Loopdiureticssare recommended for thectreatmentcofkcongestionqinprHF patient. cHowever,cdiureticvresistanceeispavcommon problem issueiinpacuteqdecompensationtofcadvancedochronicrheartwfailureq(ACHF) patients and established prognostic factor. Some early reports estimated the prevalence of diuretic resistance about 20%-30% in HF population. In this review, we will be discuss how to diagnose the advancedvheartufailurepand the underlying mechanism of diuretic resistancebin HF patients. We also describe pharmacologicalvand non-pharmacologicalstrategies to overcome this issue.

Download Full-text

Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: A scheme for the progression of cardiac dysfunction

Proceedings of the National Academy of Sciences ◽

10.1073/pnas.0401944101 ◽

2004 ◽

Vol 101 (19) ◽

pp. 7381-7385 ◽

Cited By ~ 42

Author(s):

T. Toyo-Oka ◽

T. Kawada ◽

J. Nakata ◽

H. Xie ◽

M. Urabe ◽

...

Keyword(s):

Heart Failure ◽

Cardiac Dysfunction ◽

Advanced Heart Failure ◽

Common Pathway

Download Full-text

Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction

Children ◽

10.3390/children8100872 ◽

2021 ◽

Vol 8 (10) ◽

pp. 872

Author(s):

Hari P. Tunuguntla ◽

Kriti Puri ◽

Susan W. Denfield

Keyword(s):

Heart Failure ◽

Cancer Therapy ◽

Cardiac Dysfunction ◽

Late Onset ◽

Advanced Heart Failure ◽

Cancer Therapies ◽

Children With Cancer ◽

Pericardial Disease ◽

Symptomatic Heart Failure ◽

Childhood Malignancies

The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction as a result of exposure to chemotherapy and/or radiation. Anthracyclines remain the most common cause of chemotherapy-induced cardiomyopathy (CCM) with varying clinical presentations including: acute, early onset, and late-onset. Many individuals develop cardiac dysfunction over the long-term, ranging from subclinical cardiac dysfunction to end-stage symptomatic heart failure. The focus of this review is on characterization of symptomatic heart failure in children with cancer therapy-related cardiac dysfunction (CTRCD) primarily due to CCM and utilization of advanced heart failure therapies, including ventricular assist device (VAD) support and heart transplantation, with consideration of unique patient-related factors.

Download Full-text